The Latest Cardiac and Vascular News
Investment supports Rebound Medical’s DME services for orthopedic and vascular physician practices DANBURY, Conn., April 8, 2024 /PRNewswire/ — Castleford Capital (“Castleford”), a private equity firm focused on investing in healthcare and pharmaceutical services companies, today…
NEW YORK, April 8, 2024 /PRNewswire/ — Acarix, a leader in acoustic-based Cardiac Diagnostics, is pleased to announce the results from a 2024 American College of Cardiology (ACC) poster presentation by Suzanne Baron, MD, MSc, Director of Interventional Cardiology Research, Massachusetts…
EHRA late-breaking data: Results highlight efficacy, safety, and durability of the novel PFA catheter that is fully integrated with Affera™ Mapping and Ablation System DUBLIN and BERLIN, April 8, 2024 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology,…
Caristo’s CaRi-Heart® AI Technology used to monitor effects of Orticumab detected a reduction in coronary inflammation and predicted a 50% reduction in risk of fatal cardiac events among patients with high coronary artery inflammation ATLANTA, April 8, 2024 /PRNewswire/ — Abcentra LLC, a…
Poster Presentation Details Visualization of Low-Voltage ECGs Hidden by Ablation Energy Artifact COPENHAGEN, Denmark, April 8, 2024 /PRNewswire/ — CathVision today announced data from the PVISION trial demonstrating the ability of the ECGenius System’s predictive noise filter to increase…
New data support the feasibility of machine learned algorithms to detect elevated left ventricular end-diastolic pressure (LVEDP) Data collected using the CorVista System®, the world’s first non-invasive point-of-care solution approved for evaluating the presence of coronary artery disease and pulmonary hypertension April 07, 2024 09:00 AM Eastern Daylight Time BETHESDA, […]
– In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression
New data from largest head-to-head randomized control TAVR trial demonstrates non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien™ at one year DUBLIN and ATLANTA, April 7, 2024 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in…
Basel, April 6, 2024 – Novartis today announced new data demonstrating the early addition of twice-yearly* Leqvio® (inclisiran) to maximally tolerated statin therapy, prior to guideline-recommended ezetimibe, in a real-world setting significantly reduced low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), including those with a history of an ASCVD-related event, who could not reach their goal on statin therapy alone1. The late-breaking data were presented at the 2024 American College of Cardiology’s Annual Scientific Session & Expo and simultaneously published in the Journal of the American College of Cardiology.
— Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels — — Lp(a) Results Published Simultaneously in the Journal of the American College of Cardiology (JACC) –
